Orexo Seeks FDA Approval for Opioid Dependency Drug

Swedish pharmaceutical company Orexo plans to submit OX219, a treatment for opioid dependency, for FDA approval in the U.S.

Advertisement

According to a company release, Orexo is now “on track” to seek approval following an initial consultation with the regulatory organization, which reviewed the clinical program, pre-clinical documentation and manufacturing and control plans for the drug.

Related Articles on Pain Management:

Relmada Raises $3M to Develop LevoCap Painkiller
Pain Specialist Dr. David Cheng Joins Midwest Orthopaedics
Middle Fork Surgery Center Visited by Oregon’s Co-Speaker of the House

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.